Brexafemme Approved for Vulvovaginal Candidiasis
The approval was based on data from two phase 3 trials that compared Brexafemme to placebo in female patients aged 12 years and older with acute VVC.
Fungal Infections
Oteseconazole Promising for Recurrent Vulvovaginal Candidiasis
Oteseconazole is a novel oral inhibitor of fungal CYP51.
Ibrexafungerp Gets Priority Review for Vulvovaginal Candidiasis
The FDA has accepted for filing and granted Priority Review to the NDA for ibrexafungerp (SCY-078; Scynexis) for the treatment of vulvovaginal candidiasis.
Ibrexafungerp NDA for Vulvovaginal Candidiasis Submitted for Review
Ibrexafungerp is an investigational oral antifungal agent representing a novel therapeutic class of structurally-distinct glucan synthase inhibitors known as triterpenoids.
Managing SGLT2 Inhibitor-Associated Genital Mycotic Infections
Genital mycotic infection is listed as a potential adverse effect of the SGLT2 inhibitor class.
Musculoskeletal Malformations Up With Fluconazole in Pregnancy
But no increase seen in conotruncal malformations, oral clefts with use of oral fluconazole in first trimester
Generic Version of Antifungal Drug Mycamine Now Available
Fresenius Kabi announced the launch of Micafungin for Injection, a generic version of Mycamine (micafungin for injection; Astellas Pharma).
FDA Approves Jublia for Onychomycosis in Pediatric Patients
At week 52, results showed that 65% of patients achieved mycologic cure.
Ibrexafungerp Effective in Second Phase 3 Vulvovaginal Candidiasis Trial
Scynexis announced positive topline results from a second phase 3 study of ibrexafungerp for the treatment of vulvovaginal candidiasis.
App Allows Clinicians to Report on New Uses of FDA-Approved Drugs for Difficult-to-Treat Infectious Diseases
The Food and Drug Administration (FDA) has launched CURE ID, an internet-based repository that allows clinicians to report their experiences using existing FDA-approved drugs for difficult-to-treat infections.
